Saventic Health funding news – Warsaw-based Saventic Health has Raised €1.9 Million in Bridge Funding

The funds will help Saventic expand into new markets like Europe, South America, and Canada, and prepare for a larger Series A funding round soon.

Read also - Alstin Capital funding news – Munich-based Alstin Capital has Secured €175 Million in Funding

Szymon Piątkowski, Co-founder and CEO of Saventic Health said, “Our international presence confirms that our algorithms are effective and well-received by our clients and partners, The healthcare, biotechnology, and innovation sectors are currently building a completely new market from scratch, fueled by the AI revolution. Our startup culture and highly skilled team enable us to be one of the key players in this field.”

Saventic Health, founded in 2019 by Szymon Piątkowski and Professor Grzegorz Basak, creates AI algorithms to help diagnose rare diseases more accurately and quickly than traditional methods. The company currently uses 50 algorithms and has diagnosed over 200 people with rare conditions in the past year.

Its solutions are used worldwide, with partnerships with 11 of the top 30 pharmaceutical companies and over 30 clinics and hospitals in Poland, Germany, France, Brazil, and Canada.

The Saventic Health team of 40 includes doctors, data scientists, and engineers, all working together to improve healthcare through AI.

The company's AI technology analyzes medical records to help doctors identify rare diseases that affect 450 million people worldwide. It suggests next steps for doctors, making the process much faster and more accurate than traditional methods, which can take 7-12 years to diagnose and often succeed only 2-4% of the time.

Piątkowski added, “We are now focusing on entering the Austrian, Swedish, Spanish, and Italian markets, leveraging the fact that our algorithms are registered as medical devices across the European Union. We are also expanding our presence in South America, where our solutions are similarly certified as medical products. In addition to Brazil, where we already have ongoing projects, we are beginning operations in Colombia, Peru, and other digitally advanced countries in the region,”.

The company plans to grow by entering new markets and expanding into countries like Colombia and Peru. Saventic Health also aims to enter the U.S. market after completing its Series A funding round.

This new funding is the first investment from TNI Fund, part of Kluz Ventures, which focuses on innovative healthcare technologies.

Artur Kluz, General Partner at TNI Fund said, “Our fund focuses on breakthrough technologies in healthcare and their practical applications to solve global problems. Saventic Health provides innovative patient diagnostic solutions, which we believe represent the future of healthcare,”.

Tomasz Biłous, Managing Partner at 4growth VC said, "4growth VC, which initially invested €2 million in Saventic Health in 2022, also increased its stake in this round. The inclusion of a U.S. fund among its investors confirms Saventic Health’s global potential, The company is already active on three continents and has global agreements with the largest pharmaceutical players. Thanks to fully digitalized processes, Saventic Health can execute projects for its clients and assist in diagnosing patients wherever needed, enabling dynamic international growth.”

Ksenia Wójcik Karasiewicz, CEO of NCBR Investment Fund said “We are pleased to witness the company’s dynamic development, which reassures us about the quality of this investment. Saventic Health’s current expansion and the ambitious plans of its founders have convinced us to increase our capital commitment. This highlights the importance of public-private capital collaboration, which jointly provides innovative Polish companies with greater opportunities to build global potential,”.

About Saventic Health

Saventic Health is a med-tech company that develops AI algorithms to help doctors diagnose rare diseases early by analyzing patients' medical records, including lab test results, X-rays, and other medical data.